EcoDrugPlus

Natriuretic Peptide Receptor 2

Ensembl ID : ENSSLUG00000016166
Gene Symbol: NPR2
3 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSSLUG00000005754
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSLUG00000001318
Gene Symbol: LOC116054312
3 Cross references
201 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSLUG00000014616
Gene Symbol: LOC116062871
3 Cross references
196 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSSLUG00000004564
Gene Symbol: NPY2R
1 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSSLUG00000006201
Gene Symbol: LOC116052144
3 Cross references
176 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSSLUG00000000953
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSSLUG00000005234
Gene Symbol: NTRK2
1 Cross references
207 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSSLUG00000012570
Gene Symbol: NTRK3
1 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSSLUG00000024999
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSSLUG00000011736
Gene Symbol: NTRK1
1 Cross references
199 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSSLUG00000016986
Gene Symbol: NTRK2B
1 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).